DK1044014T3 - Middel til behandling af allergiske eller hypersensitivitets-tilstande - Google Patents

Middel til behandling af allergiske eller hypersensitivitets-tilstande

Info

Publication number
DK1044014T3
DK1044014T3 DK99900567T DK99900567T DK1044014T3 DK 1044014 T3 DK1044014 T3 DK 1044014T3 DK 99900567 T DK99900567 T DK 99900567T DK 99900567 T DK99900567 T DK 99900567T DK 1044014 T3 DK1044014 T3 DK 1044014T3
Authority
DK
Denmark
Prior art keywords
agent
allergic
treatment
hypersensitivity
hypersensitivity conditions
Prior art date
Application number
DK99900567T
Other languages
Danish (da)
English (en)
Inventor
Neil Andrew Williams
Timothy Raymond Hirst
John Bienenstock
Original Assignee
Trident Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Trident Pharmaceuticals Inc filed Critical Trident Pharmaceuticals Inc
Application granted granted Critical
Publication of DK1044014T3 publication Critical patent/DK1044014T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/025—Enterobacteriales, e.g. Enterobacter
    • A61K39/0258—Escherichia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/164—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/45—Transferases (2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/14—Decongestants or antiallergics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/24—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Enterobacteriaceae (F), e.g. Citrobacter, Serratia, Proteus, Providencia, Morganella, Yersinia
    • C07K14/245—Escherichia (G)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/502—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects
    • G01N33/5041—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects involving analysis of members of signalling pathways
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A61K2039/577—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 tolerising response
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/02—Screening involving studying the effect of compounds C on the interaction between interacting molecules A and B (e.g. A = enzyme and B = substrate for A, or A = receptor and B = ligand for the receptor)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Pulmonology (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Cell Biology (AREA)
  • Pathology (AREA)
  • Biotechnology (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Dermatology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Biophysics (AREA)
  • Toxicology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Genetics & Genomics (AREA)
  • Mycology (AREA)
DK99900567T 1998-01-09 1999-01-08 Middel til behandling af allergiske eller hypersensitivitets-tilstande DK1044014T3 (da)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB9800487.2A GB9800487D0 (en) 1998-01-09 1998-01-09 Therapies

Publications (1)

Publication Number Publication Date
DK1044014T3 true DK1044014T3 (da) 2006-11-13

Family

ID=10825085

Family Applications (1)

Application Number Title Priority Date Filing Date
DK99900567T DK1044014T3 (da) 1998-01-09 1999-01-08 Middel til behandling af allergiske eller hypersensitivitets-tilstande

Country Status (14)

Country Link
US (4) US7208155B1 (ja)
EP (2) EP1044014B9 (ja)
JP (5) JP2002500194A (ja)
AT (1) ATE335501T1 (ja)
AU (1) AU762478B2 (ja)
CA (1) CA2317443C (ja)
CY (1) CY1105651T1 (ja)
DE (1) DE69932702T2 (ja)
DK (1) DK1044014T3 (ja)
ES (1) ES2270575T3 (ja)
GB (2) GB9800487D0 (ja)
NZ (1) NZ526218A (ja)
PT (1) PT1044014E (ja)
WO (1) WO1999034817A1 (ja)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9800487D0 (en) * 1998-01-09 1998-03-04 Oratol Limited Therapies
EP1964570B1 (de) 2007-03-02 2012-11-21 Protectimmun GmbH Pharmazeutische Zusammensetzung zum Schutz vor Allergien und entzündlichen Erkrankungen
WO2010020379A1 (en) 2008-08-16 2010-02-25 Protectimmun Gmbh Composition for prevention and treatment of allergic and/or inflammatory diseases
US8241608B2 (en) * 2010-03-23 2012-08-14 Development Center For Biotechnology Treating allergy with detoxified E. coli heat-labile enterotoxin
WO2012049312A1 (en) * 2010-10-15 2012-04-19 Alk-Abelló A/S Suppression of a type 1 hypersensitivity immune response with an unrelated antigen
US9616114B1 (en) 2014-09-18 2017-04-11 David Gordon Bermudes Modified bacteria having improved pharmacokinetics and tumor colonization enhancing antitumor activity
US11129906B1 (en) 2016-12-07 2021-09-28 David Gordon Bermudes Chimeric protein toxins for expression by therapeutic bacteria
US11180535B1 (en) 2016-12-07 2021-11-23 David Gordon Bermudes Saccharide binding, tumor penetration, and cytotoxic antitumor chimeric peptides from therapeutic bacteria
US11471497B1 (en) 2019-03-13 2022-10-18 David Gordon Bermudes Copper chelation therapeutics
US10973908B1 (en) 2020-05-14 2021-04-13 David Gordon Bermudes Expression of SARS-CoV-2 spike protein receptor binding domain in attenuated salmonella as a vaccine
US20220040294A1 (en) * 2020-08-07 2022-02-10 Robert E. Coifman Administration of vaccines to sites of temporally induced cell-mediated hypersensitivity reactions, to facilitate the development of protective sensitization against infectious diseases and cancers

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5614611A (en) 1987-12-31 1997-03-25 Tanox Biosystems, Inc. Humanized monoclonal antibodies binding to IgE-bearing B cells but not basophils
WO1991012818A1 (en) 1990-02-23 1991-09-05 Immulogic Pharmaceutical Corporation Superantigen induced immune non-responsiveness
US5681571A (en) * 1993-10-08 1997-10-28 Duotol Ab Immunological tolerance-inducing agent
DE4430041A1 (de) * 1994-08-24 1996-02-29 Milupa Ag Allergieprotektive Formelnahrung
US20010036917A1 (en) * 1995-07-05 2001-11-01 Williams Neil Andrew Therapeutic agents
GB9513733D0 (en) 1995-07-05 1995-09-06 Univ Bristol Therapeutic agents
US5980898A (en) * 1996-11-14 1999-11-09 The United States Of America As Represented By The U.S. Army Medical Research & Material Command Adjuvant for transcutaneous immunization
US7097845B2 (en) 1997-04-23 2006-08-29 Jacob Sten Petersen Combinations of antigen and mucosal binding component for inducing specific immunological tolerance
GB9800487D0 (en) * 1998-01-09 1998-03-04 Oratol Limited Therapies
GB9819484D0 (en) * 1998-09-07 1998-10-28 Univ Bristol Therapeutic agents

Also Published As

Publication number Publication date
DE69932702D1 (de) 2006-09-21
EP1044014B1 (en) 2006-08-09
JP2002500194A (ja) 2002-01-08
EP1044014A1 (en) 2000-10-18
GB9800487D0 (en) 1998-03-04
US7208155B1 (en) 2007-04-24
NZ526218A (en) 2004-10-29
EP1736170A3 (en) 2008-08-20
GB0014295D0 (en) 2000-08-02
PT1044014E (pt) 2006-11-30
US20150165010A1 (en) 2015-06-18
ATE335501T1 (de) 2006-09-15
DE69932702T2 (de) 2007-08-16
GB2347625A (en) 2000-09-13
CY1105651T1 (el) 2010-12-22
JP2013151568A (ja) 2013-08-08
ES2270575T3 (es) 2007-04-01
EP1044014B9 (en) 2007-01-03
JP2015166397A (ja) 2015-09-24
EP1736170A2 (en) 2006-12-27
US20080206284A1 (en) 2008-08-28
US8357372B2 (en) 2013-01-22
CA2317443A1 (en) 1999-07-15
CA2317443C (en) 2009-06-09
US8992940B2 (en) 2015-03-31
JP2017081977A (ja) 2017-05-18
US20130345114A1 (en) 2013-12-26
WO1999034817A1 (en) 1999-07-15
AU1978299A (en) 1999-07-26
AU762478B2 (en) 2003-06-26
JP2009161568A (ja) 2009-07-23

Similar Documents

Publication Publication Date Title
PT92131A (pt) Processo para a preparacao de meios para aplicacao transdermicacontendo gestodeno
ES2058725T3 (es) Aplicacion transdermica de 2-amino-6-n-propilamino-4,5,6,7-tetrahidrobenzotiazol.
ES2170250T3 (es) Articulo absorbente desechable que tiene una lamina superior con locion y que contiene un emoliente y un agente inmovilizante de poliester de poliol.
BR9913351A (pt) Artigos absorventes descartáveis com adesivo aperfeiçoado para acoplamento à pele
ATE205391T1 (de) Nimesulid zur aüsserlichen anwendung
DK1044014T3 (da) Middel til behandling af allergiske eller hypersensitivitets-tilstande
BR9403783A (pt) Uso de uma composição cosmética
ATE226014T1 (de) Prophylaktische behandlung der allergischen kontaktdermatitis
DK261490D0 (da) New pharmaceutical compound
TR199901772T2 (ja)
ATE292975T1 (de) Verwendung von tetrahydolipstatin in der behandlung von diabetes typ ii
DE59300135D1 (de) Sulfonylbenzyl-substituierte Benzo- und Pyridopyridone.
DK36889A (da) Anvendelse af et benzamidderivat til fremstilling af et middel til behandling eller forebyggelse af kognitive lidelser
DK1063981T3 (da) Anvendelse af selegilin eller desmethylselegilin til behandling af sår, brandsår og dermatologiske skader
MX9302487A (es) Piridonas sustituidas por bifenilmetilo, procedimiento para su obtencion y medicamentos que las contienen.
DE59003020D1 (de) Piroxicam enthaltende pharmazeutische Zusammensetzung zur topischen Anwendung.
DE59106547D1 (de) Mittel zur oxidativen färbung von haaren und neue 5-halogen-2,4-diaminoalkylbenzole.
DK631989A (da) Anti-plakmiddel og/eller middel til behandling af lidelser i mundhulen
DE3484355D1 (de) Gefaerbte wasserfreie mittel fuer kosmetische, medizinische und aehnliche zwecke, sowie deren herstellung.
EP0270841A3 (de) 2-Methyl-3-(p-methyl-phenyl)-propionitril, dessen Herstellung und Verwendung als Riechstoff
DK0834316T3 (da) Anvendelse af sulbutiamin til behandling af psykomotoriske eller psykointellektuelle problemer
DE69104656D1 (de) Heilende Zusammensetzung zur örtlichen Anwendung.
DE3764855D1 (de) Mittel zur wachstumsfoerderung der haare.
DK158989D0 (da) Fremgangsmaade til enzymatisk afhaaring af huder eller skind
SE8802040D0 (sv) New use